Avinger, Inc. (AVGR)
USD 0.47
(-20.74%)
USD 0.47
(-20.74%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -16.34 Million USD | 4.46% |
| 2022 | -15.76 Million USD | -1.23% |
| 2021 | -17.41 Million USD | 9.13% |
| 2020 | -16.41 Million USD | 10.39% |
| 2019 | -16.4 Million USD | 12.32% |
| 2018 | -20.58 Million USD | 43.96% |
| 2017 | -40.95 Million USD | 22.12% |
| 2016 | -49.09 Million USD | -24.46% |
| 2015 | -40.87 Million USD | -62.44% |
| 2014 | -24.48 Million USD | 29.43% |
| 2013 | -35.45 Million USD | -7.27% |
| 2012 | -33.07 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -3.75 Million USD | 14.49% |
| 2024 Q1 | -4.71 Million USD | -4.1% |
| 2023 Q4 | -4.29 Million USD | -6.42% |
| 2023 FY | - USD | 4.46% |
| 2023 Q2 | -3.66 Million USD | 13.9% |
| 2023 Q1 | -4.25 Million USD | -11.81% |
| 2023 Q3 | -4.03 Million USD | -10.16% |
| 2022 FY | - USD | -1.23% |
| 2022 Q4 | -3.8 Million USD | -4.88% |
| 2022 Q3 | -3.62 Million USD | 1.87% |
| 2022 Q2 | -3.69 Million USD | 21.15% |
| 2022 Q1 | -4.68 Million USD | -2.72% |
| 2021 FY | - USD | 9.13% |
| 2021 Q2 | -1.87 Million USD | 57.87% |
| 2021 Q3 | -4.33 Million USD | -130.71% |
| 2021 Q1 | -4.46 Million USD | -6.6% |
| 2021 Q4 | -4.56 Million USD | -5.24% |
| 2020 Q2 | -3.35 Million USD | 35.77% |
| 2020 Q3 | -3.87 Million USD | -15.46% |
| 2020 Q1 | -5.22 Million USD | -4.33% |
| 2020 Q4 | -4.18 Million USD | -7.92% |
| 2020 FY | - USD | 10.39% |
| 2019 Q2 | -4.7 Million USD | -4.46% |
| 2019 FY | - USD | 12.32% |
| 2019 Q4 | -5.01 Million USD | -24.65% |
| 2019 Q3 | -4.02 Million USD | 14.58% |
| 2019 Q1 | -4.5 Million USD | 22.77% |
| 2018 Q3 | -4.84 Million USD | 6.72% |
| 2018 FY | - USD | 43.96% |
| 2018 Q4 | -5.83 Million USD | -20.34% |
| 2018 Q2 | -5.19 Million USD | 7.36% |
| 2018 Q1 | -5.6 Million USD | 13.21% |
| 2017 Q2 | -10.28 Million USD | 25.4% |
| 2017 Q4 | -6.46 Million USD | 23.32% |
| 2017 Q1 | -13.79 Million USD | -15.65% |
| 2017 FY | - USD | 22.12% |
| 2017 Q3 | -8.42 Million USD | 18.09% |
| 2016 Q4 | -11.92 Million USD | -4.59% |
| 2016 FY | - USD | -24.46% |
| 2016 Q3 | -11.4 Million USD | 7.02% |
| 2016 Q2 | -12.26 Million USD | 18.21% |
| 2016 Q1 | -14.99 Million USD | -22.03% |
| 2015 FY | - USD | -62.44% |
| 2015 Q2 | -9.07 Million USD | 3.69% |
| 2015 Q1 | -9.42 Million USD | -35.1% |
| 2015 Q4 | -12.28 Million USD | -24.57% |
| 2015 Q3 | -9.86 Million USD | -8.72% |
| 2014 Q2 | -5.14 Million USD | 13.81% |
| 2014 Q3 | -5.8 Million USD | -12.69% |
| 2014 Q4 | -6.97 Million USD | -20.24% |
| 2014 Q1 | -5.97 Million USD | 14.89% |
| 2014 FY | - USD | 29.43% |
| 2013 Q3 | -8.01 Million USD | 21.54% |
| 2013 Q2 | -10.21 Million USD | 0.0% |
| 2013 FY | - USD | -7.27% |
| 2013 Q1 | -10.21 Million USD | 0.0% |
| 2013 Q4 | -7.01 Million USD | 12.47% |
| 2012 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Akoya Biosciences, Inc. | -45.63 Million USD | 64.179% |
| AngioDynamics, Inc. | -14.29 Million USD | -14.372% |
| AtriCure, Inc. | -8.1 Million USD | -101.578% |
| Azenta, Inc. | 55.15 Million USD | 129.639% |
| BioLife Solutions, Inc. | -45.23 Million USD | 63.867% |
| The Cooper Companies, Inc. | 882.8 Million USD | 101.852% |
| Daxor Corporation | 329.74 Thousand USD | 5057.239% |
| Ekso Bionics Holdings, Inc. | -13.19 Million USD | -23.852% |
| Femasys Inc. | -13.16 Million USD | -24.121% |
| GlucoTrack, Inc. | -7.09 Million USD | -130.518% |
| Harvard Bioscience, Inc. | 9.49 Million USD | 272.19% |
| Hologic, Inc. | 1.29 Billion USD | 101.261% |
| ICU Medical, Inc. | 307.69 Million USD | 105.312% |
| Intuitive Surgical, Inc. | 2.39 Billion USD | 100.683% |
| KORU Medical Systems, Inc. | -9.39 Million USD | -73.901% |
| LeMaitre Vascular, Inc. | 48.99 Million USD | 133.366% |
| Innovative Eyewear, Inc. | -6.57 Million USD | -148.603% |
| Innovative Eyewear, Inc. | -6.57 Million USD | -148.603% |
| Masimo Corporation | 236.7 Million USD | 106.906% |
| Microbot Medical Inc. | -10.63 Million USD | -53.715% |
| Meihua International Medical Technologies Co., Ltd. | 15.77 Million USD | 203.649% |
| Merit Medical Systems, Inc. | 231.44 Million USD | 107.063% |
| Nephros, Inc. | -1.37 Million USD | -1085.352% |
| NovoCure Limited | -175.86 Million USD | 90.705% |
| NEXGEL, Inc. | -2.73 Million USD | -498.755% |
| NEXGEL, Inc. | -2.73 Million USD | -498.755% |
| Singular Genomics Systems, Inc. | -86.49 Million USD | 81.102% |
| OraSure Technologies, Inc. | 76.15 Million USD | 121.463% |
| Pro-Dex, Inc. | 8.33 Million USD | 296.16% |
| Pulse Biosciences, Inc. | -42.36 Million USD | 61.418% |
| Predictive Oncology Inc. | -13.18 Million USD | -24.002% |
| Precision Optics Corporation, Inc. | -2.51 Million USD | -550.729% |
| QuidelOrtho Corporation | 545.6 Million USD | 102.996% |
| Repligen Corporation | 124.29 Million USD | 113.151% |
| Sanara MedTech Inc. | -289.09 Thousand USD | -5554.158% |
| STAAR Surgical Company | 33.22 Million USD | 149.204% |
| Sharps Technology, Inc. | -8.98 Million USD | -82.019% |
| Utah Medical Products, Inc. | 24.8 Million USD | 165.898% |
| DENTSPLY SIRONA Inc. | 232 Million USD | 107.046% |
| Jin Medical International Ltd. | 3.44 Million USD | 574.776% |